Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-20-009834
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-14 19:40:17
Reporting Period:
2020-02-13
Accepted Time:
2020-02-14 19:40:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1080709 Arena Pharmaceuticals Inc ARNA Pharmaceutical Preparations (2834) 232908305
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1677036 Robert Kevin Lind C/o Arena Pharmaceuticals, Inc.
6154 Nancy Ridge Drive
San Diego CA 92121
Executive Vp And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-02-13 2,500 $19.40 5,957 No 4 M Direct
Common Stock Acquisiton 2020-02-13 2,000 $35.60 7,957 No 4 M Direct
Common Stock Disposition 2020-02-13 4,500 $55.00 3,457 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2020-02-13 2,500 $0.00 2,500 $19.40
Common Stock Employee Stock Option (right to buy) Disposition 2020-02-13 2,000 $0.00 2,000 $35.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
77,500 2023-06-15 No 4 M Direct
128,000 2025-01-19 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
  2. The options vest over four years, with 25% of the shares subject to the option vesting on June 15, 2017, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.
  3. The options vest over four years, with 25% of the shares subject to the option vesting on January 19, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.